Physician profile
Taha Bat
NPI 1679915102
$81,253.25
in general payments reported to CMS, 2019-2025
8 companies · $11K in 2025
The $11K reported for 2025 was more than what 78% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $113 · 2023: $25K · 2024: $46K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $72K · Travel and Lodging: $6,538 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,500 · Food and Beverage: $1,385 · Education: $22.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $71,543.50 |
| Travel and Lodging | $6,538.17 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,500.00 |
| Food and Beverage | $1,385.23 |
| Education | $22.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $54,673.14 | 2021-2025 | Voydeya |
| Novartis Pharmaceuticals Corporation | $8,979.09 | 2023-2025 | Fabhalta |
| Genzyme Corporation | $8,815.93 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $3,575.00 | 2024 | Panhematin |
| Samsung Bioepis Co., Ltd. | $2,470.00 | 2024 | |
| Celgene Corporation | $1,500.00 | 2023 | |
| Argenx US, INC. | $1,100.00 | 2025 | Vyvgart |
| Apellis Pharmaceuticals, INC. | $140.09 | 2023 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taha Bat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.